AMG 487

Cat. No.: HY-15319
CAS No.: 473719-41-4
Molecular Formula: C₁₂H₈F₃N₅O₄
Molecular Weight: 603.59
Target: CXCR
Pathway: GPCR/G Protein; Immunology/Inflammation
Storage:
- Powder, -20°C, 3 years
- Powder, 4°C, 2 years
- In solvent, -80°C, 6 months
- In solvent, -20°C, 1 month

Solvent & Solubility

<table>
<thead>
<tr>
<th>Solvent</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMSO</td>
<td>1.6568 mL</td>
<td>8.2838 mL</td>
<td>16.5675 mL</td>
</tr>
</tbody>
</table>

Preparing Stock Solutions

10 mM: 0.1657 mL, 0.8284 mL, 1.6568 mL

Solvent & "≥" means soluble, but saturation unknown.

In Vitro

AMG 487 is an antagonist of the chemokine receptor CXCR3, which inhibits binding of ¹²⁵I-IP-10 and ¹²⁵I-ITAC to CXCR3 with IC₅₀ values of 8.0 and 8.2 nM, respectively.

IC₅₀ & Target

IC₅₀: 8.0 nM (¹²⁵I-IP-10 binding to CXCR3), 8.2 nM (¹²⁵I-ITAC binding to CXCR3)

In Vitro

AMG 487 inhibits CXCR3-mediated cell migration by the three CXCR3 chemokines (IP-10 IC₅₀=8 nM, ITAC IC₅₀=15 nM, and MIG IC₅₀=36 nM). Furthermore, AMG 487 inhibits calcium mobilization in response to ITAC (IC₅₀=5 nM)[1]. AMG487 (1 μM) develops into fewer lung metastases, and the lungs are significantly smaller than vehicle-treated lungs[2]. AMG487 abrogates proliferation/survival of C26 tumour cells[3].

In Vivo

AMG 487 (0.03-10 mg/kg, s.c.) exhibits significant reduction in cellular infiltration into the lungs in a dose dependent manner[1]. AMG487 (5 mg/kg, s.c., twice daily) develops fewer metastases than that in vehicle-treated mice[2]. AMG487 (5 mg/kg, s.c.)-treated mice exhibits fewer pulmonary nodules than the control mice in both the models.
AMG487 reduces the tumour volume[3].

**PROTOCOL**

### Kinase Assay [3]

Cells are then lysed and sonicated in 50 mM Hepes pH 7.5, 150 mM NaCl, 20 mM EDTA, 1 mM PMSF, 10 μg/mL leupeptin, 2 μg/mL aprotinin and 0.2% NP-40. Equal amount of lysates are mixed in substrate buffer (50 mM Hepes, 100 mM NaCl, 1 mM EDTA, 10% sucrose, 0.5% CHAPS, 5 mM dithiothreitol) with Ac-DEVD-AMC substrate and caspase-3/7 substrate in a microtiter plate. Production of fluorogenic substrate is measured continuously at 37°C in a spectrophotometer Ascent Fluoroskan and the caspase activity (expressed as U/mg of protein) is defined as the amount of enzyme cleaving 1 nmol of substrate/min.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### Cell Assay [3]

Colon cancer cells are seeded at a density of 10^4 cells cm^-2 and incubated either in serum-enriched medium or in base medium (containing 0.1% bovine serum albumin, BSA) supplemented or not with various concentrations of rCXCL9, rCXCL10 and rCXCL11 for the indicated periods of time before being either trypsin-detached, collected and enumerated or re-fed with fresh medium for 3 days, harvested and enumerated. The morphology of the CRC cells is observed through an inverted optical microscope at ×20 magnification, and photographs are taken at day 7.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### Animal Administration [2]

Local tumor growth and spontaneous metastasis are evaluated by injecting 3×10^5 viable tumor cells s.c. proximal to the right abdominal mammary gland of syngeneic female mice. Tumor diameters are measured by caliper twice weekly, and mice are euthanized on an individual basis when the s.c. tumor measured 18 mm in diameter or earlier if the mouse seemed moribund. The lungs are removed and weighed, and surface tumor colonies are quantified in a blinded fashion under a dissecting microscope. Experimental metastasis is evaluated by injecting 9×10^4 viable tumor cells i.v. into the lateral tail vein of syngeneic female mice. All mice are euthanized on day 21 posttransplantation or earlier if the mice seemed moribund. The lungs are removed and weighed, and surface tumor colonies are quantified in a blinded fashion under a dissecting microscope. A 50% hydroxypropyl-β-cyclodextrin solution is prepared; at 20%, this solution serves as the vehicle. AMG487 is added to the 50% solution, and it is incubated in a sonicating water bath for 2 hours with occasional vortexing. Distilled water is added to give the appropriate final concentration of AMG487 in 20% of hydroxypropyl-β-cyclodextrin.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**CUSTOMER VALIDATION**


See more customer validations on www.MedChemExpress.com

**REFERENCES**


Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898            Fax: 609-228-5909            E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA